BRANDY ELING: Open Payments
NPI 1700487741 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,730 in 49 payments from 20 companies in 2025. Trend: 2023 $437 · 2024 $729 · 2025 $1,730
Food & beverage: $1,176Education: $379Consulting: $175
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 12 | $622 |
| ABBVIE INC. | 9 | $219 |
| Alexion Pharmaceuticals, Inc. | 1 | $175 |
| BeOne Medicines USA, Inc. | 1 | $131 |
| Celgene Corporation | 3 | $76 |
| PFIZER INC. | 4 | $73 |
| KYOWA KIRIN, INC. | 2 | $52 |
| Incyte Corporation | 2 | $44 |
| Syndax Pharmaceuticals, Inc. | 2 | $43 |
| SOBI, INC | 2 | $41 |
Products named: Xospata, ULTOMIRIS, BRUKINSA, EPKINLY, REBLOZYL, ELREXFIO, IMBRUVICA, POTELIGEO.
Industry payments across CO — which companies pay providers there.
